<DOC>
	<DOCNO>NCT00935532</DOCNO>
	<brief_summary>The objective clinical trial compare effect exenatide weekly insulin glargine blood glucose control , body weight , lipid , safety , tolerability .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Exenatide Once-Weekly Injection Compared Once-Daily Insulin Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>present type 2 diabetes mellitus HbA1c 7.1 % 11.0 % inclusive body mass index ( BMI ) &gt; 18kg/m2 &lt; 35kg/m2 , inclusive treat stable dose regimen either biguanide ( BG ) alone , BG + thiazolidinedione ( TZD ) , BG + sulfonylurea ( SU ) , BG + TZD + SU 90 day prior study start Have receive chronic ( &gt; 14 consecutive day ) systemic adrenocorticosteroid therapy oral , intravenous , intramuscular route intraarticular steroid injection within 4 week prior study start . Have treat drug promote weight loss within 90 day prior study start . Have treat drug directly affect gastrointestinal motility &gt; 21 consecutive day within 90 day prior study start . Have prior exposure exenatide BID QW participate clinical trial exenatide BID QW ( include case study drug administer ) . Have treat &gt; 2 consecutive week follow excluded medication within 90 day prior study start : Insulin , Dipeptidyl peptidase4 ( DPP4 ) inhibitor , GLP1 analog Have receive treatment within 30 day prior study start drug receive regulatory approval indication . Are currently enrol clinical study participate complete clinical study within 30 day prior study start . Have donate blood within 30 day prior study start .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>diabetes ; exenatide weekly ; Byetta ; glargine ; Lantus ; Amylin ; Lilly</keyword>
</DOC>